Mostrando 2 resultados de: 2
Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: A SENDO Foundation study
ArticleAbstract: Purpose: To assess the pharmacodynamic effects of nimotuzumab, an anti-epidermal growth factor recepPalabras claves:Autores:Albanell J., Bellosillo B., Campas C., Cedeño M., Corominas J.M., Corradino I., Cruz T., Gascon P., Gracias E., Iznaga N., Marsoni S., Osorio M., Rojo F., Rovira A., Serrano S., Sessa C., Tania Crombet, Villena N.Fuentes:scopusUse of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
ArticleAbstract: Purpose: To evaluate safety and preliminary efficacy of the humanized anti-epidermal growth factor rPalabras claves:Autores:Alvarez D., Cruz T., Del Castillo R., Fernández E., Figueredo R., Iznaga-Escobar N., Koropatnick J., Lage Davila A., Leonard I., Mon R., Osorio M., Pérez R., Ramos M., Renginfo E., Roca C., Tania Crombet, Torres O.Fuentes:scopus